CBO: Senate Compounding, Track-and-Trace Bill to Pack a Wallop for Industry; While S 959 Will Have Little Impact on the Federal Government

FDAnews Drug Daily Bulletin

July 19, 2013  | Vol. 10 No. 140

 

The private sector will bear the brunt of costs from combined Senate legislation on track-and-trace and compounding, according to a new federal cost estimate that casts doubt on an already precarious legislative effort. A Monday report from the Congressional Budget Office (CBO) estimates that S. 959, the Pharmaceutical Quality, Security and Accountability Act, will have little impact on the federal government.
Drug Industry Daily